HUTCHMED licenses cancer drug for $110 million

• HUTCHMED signed a global licensing agreement for HMPL-A830 with a GSK subsidiary for a $110 million upfront payment.
• The deal includes up to $1.185 billion in additional milestone payments and tiered royalties.
• HUTCHMED will retain rights in Greater China and lead the Phase I trial planned for H2 2026.

HUTCHMED (NASDAQ:HCM) signed an exclusive development and license agreement with a GSK subsidiary for HMPL-A830, a KRAS-EGFR Antibody-Targeted Therapy Conjugate, covering worldwide rights outside Mainland China, Hong Kong, Macau, and Taiwan.

Under the agreement, HUTCHMED will receive a US$110 million upfront payment, while the deal includes up to US$1.185 billion in additional development, regulatory, and commercial milestone payments.

The agreement also includes tiered royalties on net sales, while HUTCHMED retains full rights in Greater China and will lead the global Phase I clinical trial, which is expected to begin in the second half of 2026.

HUTCHMED stated that the Phase I trial will initially evaluate HMPL-A830 in colorectal, pancreatic, and lung cancers.

HUTCHMED develops targeted therapies and cancer treatments, focusing on oncology and immunology programs for patients in China and international markets.

HMPL-A830 is designed as a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate, combining targeted antibody technology with cancer drug delivery approaches as the company advances its oncology pipeline.